SavedAdd your journal

Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2007 / Cilt: 15 - Sayı: 3

Statin therapy in coronary bypass patients

Koroner bypasslı hastalarda statin tedavisi

Alp AYDINALP
Haldun MÜDERRİSOĞLU
Pages
263–267
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the importance of intensive and early initiation of statin therapy is addressed following coronary artery bypass surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Statins have been proven to prevent ischemic events in patients at risk for atherosclerotic coronary disease and after coronary revascularization.
📊
Key Findings & Data:They also minimize recurrent ischemic events through improving vein graft patency, and thus decrease the need for repeat revascularization procedures in patients who have undergone coronary artery bypass grafting.
💡
Conclusion & Impact:In this review, the importance of intensive and early initiation of statin therapy is addressed following coronary artery bypass surgery.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Statins have been proven to prevent ischemic events in patients at risk for atherosclerotic coronary disease and after coronary revascularization. They also minimize recurrent ischemic events through improving vein graft patency, and thus decrease the need for repeat revascularization procedures in patients who have undergone coronary artery bypass grafting. In this review, the importance of intensive and early initiation of statin therapy is addressed following coronary artery bypass surgery.

Özet

Koroner arter hastalığı gelişme riski taşıyan hastalarda ve revaskülarizasyon yapılmış hastalarda statinlerin iskemik olayları azalttığı gösterilmiştir. Statinler koroner bypasslı hastalarda, özellikle ven greftlerin açık kalmasını sağlayarak iskemik atakların tekrarını önlerler ve bu şekilde revaskülarizasyon ihtiyacını azaltırlar. Bu derlemede agresif lipid düşürücü tedavinin ve bu tedaviye erken dönemde başlamanın bypasslı hastalardaki önemi vurgulanmak istenmiştir.

🔖

Cite This Article

AYDINALP, A., MÜDERRİSOĞLU, H. (2022). Statin therapy in coronary bypass patients. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 15 - Sayı: 3, 263–267. https://ajindex.com/articles/425112

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Grondin CM. Late results of coronary artery grafting: is there a flag on the field? J Thorac Cardiovasc Surg 1984;87:161-6. 2) van Brussel BL, Plokker HW, Voors AA, Ernst SM, Kelder HC. Progression of atherosclerosis after venous coronary artery bypass graft surgery: a 15-year follow-up study. Cathet Cardiovasc Diagn 1997;41:141-50
  2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
  3. Libby P. The vascular biology of atherosclerosis. In: Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Braunwald’s heart disease. 7th ed. Philadelphia: Saunders, 2005. p. 921-39
  4. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-8
  5. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61-9
  6. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35
  7. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6: 1004-10
  8. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-90
  9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
  10. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-22
  11. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802
  12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344:1383-9
  13. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfe